Showing results (501-510 of 898) with videos related to

Sort By:
Pageof 90
Frontiers in Allergy|May 12, 2025
Erratum: A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema
Frontiers in Allergy|May 15, 2025
T2 cytokine-driven alarmin and antiviral responses in asthma: insights into immune modulation and the role of IL-4Rα targetingJelena Pesic, Juan José Nieto-Fontarigo, Katerina Pardali, et al.
Frontiers in Allergy|April 25, 2025
A randomized controlled trial evaluating prophylactic treatment of Artemisia pollinosis using azelastine hydrochloride and fluticasone propionate nasal sprayLe Cui, Na Gao, Cairong Bai, et al.
Frontiers in Allergy|May 2, 2025
Molecular allergen sensitization profile and casein threshold determination predicting the persistence of cow's milk protein allergy in Tunisia (North Africa)Yasmina Ouerdani, Imen Zamali, Yousr Galai, et al.
Frontiers in Allergy|April 18, 2025
Development and validation of a Delphi consensus-based questionnaire for the multidisciplinary management of type 2 inflammation-related diseasesFrancisco Javier Ortiz de Frutos, Carolina Cisneros, José Miguel Villacampa, et al.
Frontiers in Allergy|March 31, 2025
Corrigendum: Milk ladder: Who? When? How? Where? with the lowest risk of reactionBetul Buyuktiryaki, Ozge Soyer, Duygu Yazici, et al.
Frontiers in Allergy|March 24, 2025
Efficacy of omalizumab after discontinuation: a retrospective single-center observational study in children with severe asthmaSimone Foti Randazzese, Cecilia Lugarà, Francesca Galletta, et al.
Frontiers in Allergy|November 17, 2025
Allergen immunotherapy for the control of moderate to severe allergic asthma: an evidence-based conjoint analysis to define candidate patient profiles in Spain and PortugalJ Delgado, R Cárdenas, S Gelis, et al.
Frontiers in Allergy|September 8, 2025
One-year real-life outcomes of lanadelumab therapy in Romanian patients with hereditary angioedema due to C1-inhibitor deficiencyNoémi Anna Bara, Valentin Nădășan, Diana Deleanu
Frontiers in Allergy|October 17, 2025
Machine learning-derived genetic risk scores identify IL21 as a predictor of response to omalizumab and dupilumab in asthmaAyobami Akenroye, Chengyue Zhang, Tanawin Nopsopon, et al.
Pageof 90